Lixte Biotechnology Holdings Stock Alpha and Beta Analysis
| LIXT Stock | USD 3.78 0.06 1.56% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Lixte Biotechnology Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Lixte Biotechnology over a specified time horizon. Remember, high Lixte Biotechnology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Lixte Biotechnology's market risk premium analysis include:
Beta (0.13) | Alpha (0.28) | Risk 3.82 | Sharpe Ratio (0.1) | Expected Return (0.38) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Lixte Biotechnology Backtesting, Lixte Biotechnology Valuation, Lixte Biotechnology Correlation, Lixte Biotechnology Hype Analysis, Lixte Biotechnology Volatility, Lixte Biotechnology History and analyze Lixte Biotechnology Performance. Lixte Biotechnology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Lixte Biotechnology market risk premium is the additional return an investor will receive from holding Lixte Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lixte Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Lixte Biotechnology's performance over market.| α | -0.28 | β | -0.13 |
Lixte Biotechnology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Lixte Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how Lixte Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Lixte Biotechnology Market Price Analysis
Market price analysis indicators help investors to evaluate how Lixte Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lixte Biotechnology shares will generate the highest return on investment. By understating and applying Lixte Biotechnology stock market price indicators, traders can identify Lixte Biotechnology position entry and exit signals to maximize returns.
Lixte Biotechnology Return and Market Media
The median price of Lixte Biotechnology for the period between Wed, Oct 8, 2025 and Tue, Jan 6, 2026 is 4.28 with a coefficient of variation of 7.35. The daily time series for the period is distributed with a sample standard deviation of 0.32, arithmetic mean of 4.31, and mean deviation of 0.22. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Bernards Rene of 4473 shares of Lixte Biotechnology at 2.29 subject to Rule 16b-3 | 10/17/2025 |
2 | What recovery options are there for Lixte Biotechnology Holdings Inc. Equity Warrant - Trade Risk Report Free High Return Stock Watch Alerts - newser.com | 10/22/2025 |
3 | Is Lixte Biotechnology Holdings Inc. Equity Warrant stock reversal real or fake - July 2025 Trends Free Real-Time Market Sentiment Alerts - newser.com | 11/05/2025 |
4 | How Lixte Biotechnology Holdings Inc. Equity Warrant stock compares to market leaders - Weekly Earnings Recap Low Risk Investment Opportunities - newser.com | 11/11/2025 |
5 | How Lixte Biotechnology Holdings Inc. Equity Warrant stock compares to market leaders - 2025 Biggest Moves Weekly Watchlist for Hot Stocks - newser.com | 11/14/2025 |
6 | Is Lixte Biotechnology Holdings Inc. stock a safe buy before earnings - Portfolio Value Report Long-Term Investment Growth Plans - newser.com | 11/18/2025 |
7 | LIXTE Biotechnology Acquires Liora Technologies Proprietary Proton Therapy Platform for Cancer Treatment | 11/25/2025 |
8 | LIXTEs Strategy Comes Into Focus Building an Oncology Platform Around Complementary Modalities | 12/08/2025 |
9 | Lixte Biotechnology Holdings, Inc. Announces 4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules | 12/18/2025 |
10 | Will Lixte Biotechnology Holdings Inc. stock see insider buying - Take Profit Strategies Trusted Financial Advisors at No Cost - Bollywood Helpline | 12/23/2025 |
11 | Acquisition by Felix Lourdes of 25000 shares of Lixte Biotechnology at 4.05 subject to Rule 16b-3 | 12/24/2025 |
12 | Acquisition by Yen Yun of 100000 shares of Lixte Biotechnology subject to Rule 16b-3 | 12/29/2025 |
About Lixte Biotechnology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Lixte or other stocks. Alpha measures the amount that position in Lixte Biotechnology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2025 | 2026 (projected) | Dividend Yield | 1.43E-4 | 2.69E-4 | 1.77E-4 | Price To Sales Ratio | 70.11 | 63.1 | 56.09 |
Lixte Biotechnology Upcoming Company Events
As portrayed in its financial statements, the presentation of Lixte Biotechnology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lixte Biotechnology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Lixte Biotechnology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Lixte Biotechnology. Please utilize our Beneish M Score to check the likelihood of Lixte Biotechnology's management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Lixte Biotechnology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.